Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Elbasvir/Grazoprevir in French Subjects With Chronic HCV Genotype 4 Infection
NCT03111108Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of elbasvir + grazoprevir in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After End of Treatment, Number of Participants With >= 1 Adverse Events up to 14 weeks and 1 more. Started Jun 2017; status: completed.
02
Drugs
elbasvir + grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03111108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111108.